1. Home
  2. PFO vs ELDN Comparison

PFO vs ELDN Comparison

Compare PFO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

HOLD

Current Price

$9.47

Market Cap

123.3M

Sector

Finance

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$2.50

Market Cap

208.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFO
ELDN
Founded
1991
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.3M
208.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PFO
ELDN
Price
$9.47
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
30.5K
671.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.51%
N/A
EPS Growth
N/A
54.27
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$1.35
52 Week High
$9.90
$4.60

Technical Indicators

Market Signals
Indicator
PFO
ELDN
Relative Strength Index (RSI) 33.12 62.28
Support Level $9.34 $2.48
Resistance Level $9.56 $2.77
Average True Range (ATR) 0.07 0.16
MACD -0.03 0.04
Stochastic Oscillator 10.00 71.72

Price Performance

Historical Comparison
PFO
ELDN

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: